Related Experiment Video

Updated: Sep 30, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.3K

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Adrian Minson1,2, Constantine Tam1,2, Michael Dickinson1,2

  • 1Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.

Cancers
|March 10, 2022
PubMed

Insights

Targeted therapies are improving outcomes for indolent lymphomas like follicular lymphoma. This review covers approved and emerging small molecule inhibitors, immunomodulators, and combination therapies for these conditions.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Targeted therapies have significantly advanced lymphoma treatment, improving patient outcomes.
  • Several targeted agents are approved for indolent lymphomas, with more showing promise.
  • Indolent lymphomas include follicular lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, and marginal zone lymphoma.

Purpose of the Study:

  • To review the current landscape of targeted therapies for indolent lymphomas.
  • To discuss approved and emerging agents, including small molecule inhibitors, immunomodulators, and targeted immunotherapies.
  • To highlight promising combination therapies in indolent lymphoma treatment.

Main Methods:

  • Literature review of targeted agents for indolent lymphomas.
  • Analysis of approved therapies and agents in development.
  • Synthesis of information on various targeted therapy classes and combinations.

Main Results:

  • A range of targeted agents are available and under investigation for indolent lymphomas.
  • Small molecule inhibitors, immunomodulators, and targeted immunotherapies represent key treatment modalities.
  • Emerging combination therapies show potential for enhanced efficacy.

Conclusions:

  • Targeted therapies offer improved options and outcomes for indolent lymphoma patients.
  • The review provides a comprehensive overview of current and future targeted treatment strategies.
  • Combination approaches are a promising avenue for future indolent lymphoma management.
Keywords:
immunotherapynon-Hodgkin lymphomapersonalised medicinetargeted therapy

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
702
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K